Onderneming Opexa Therapeutics Inc Nasdaq
Aandelen
US68372T3014
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 17/11 |
Tanya Hayden
COO | Chief Operating Officer | 44 | 01-06-21 |
John M. Klopp
CTO | Chief Tech/Sci/R&D Officer | 50 | - |
Jim DeNike
IRC | Investor Relations Contact | - | - |
Bernie Paul
HRO | Human Resources Officer | 65 | 01-05-19 |
Renee Carroll
LAW | General Counsel | - | 01-01-20 |
Jason Kneeland
AUD | Comptroller/Controller/Auditor | - | 01-11-17 |
Kim Tharaldsen
SAM | Sales & Marketing | - | 05-02-18 |
Corporate Officer/Principal | 57 | 01-12-13 | |
Donald Joseph
LAW | General Counsel | 70 | 01-04-18 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
R. Clifton
DFI | Director of Finance/CFO | 51 | 17/11 |
Joshua Schafer
BRD | Director/Board Member | 53 | 17/11 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 24 463 726 | 24 463 726 ( 100,00 %) | 0 | 100,00 % |
Bedrijfsgegevens
![Adres Opexa Therapeutics Inc](https://cdn.zonebourse.com/static/address/24007935.png)
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+20,17% | 126 mld. | |
+24,67% | 118 mld. | |
+23,96% | 27,87 mld. | |
-17,74% | 20,95 mld. | |
-15,73% | 16,92 mld. | |
-15,21% | 16,18 mld. | |
+11,91% | 14,84 mld. | |
-47,10% | 14,79 mld. | |
+54,50% | 14,08 mld. |